staurosporine has been researched along with ly2090314 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brier, RA; Briere, D; Brozinick, J; Burkholder, TP; Campbell, RM; Clay, MP; Clayton, J; Cunningham, B; Diefenbacher, C; Eessalu, TE; Engler, TA; Furness, K; Hawkins, E; Henry, JR; Iversen, PW; Li, Y; Lindstrom, TD; Malhotra, S; Marquart, AL; McLean, J; Mendel, D; Misener, E; O'Toole, JC; Owens, RA; Porter, WJ; Queener, S; Reel, JK; Vaughn, R; Wagner, JR | 1 |
| Jagarlapudi, SA; Sinha, BN; Tajne, S; Vadivelan, S | 1 |
2 other study(ies) available for staurosporine and ly2090314
| Article | Year |
|---|---|
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imidazoles; Pyridines; Pyrroles; Rats; Rats, Zucker | 2004 |
Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
Topics: Algorithms; Computer Simulation; Databases, Factual; Drug Design; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Models, Chemical; Models, Molecular; Molecular Structure; Oxazines; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Stereoisomerism; Structure-Activity Relationship | 2009 |